Trial Information

Summary: Phase I/II Study of SKI-606 in Philadelphia Chromosome Positive Leukemias (Wyeth No. 3160A1-200-US)

You have been asked to participate in this research study because you have either Philadelphia Chromosome/Bcr-Abl positive (Ph+) Chronic Myelogenous Leukemia (CML) or Ph+ Acute Lymphocytic Leukemia (ALL).  The purpose of this research study is to evaluate the safety and effectiveness of SKI-606 for treatment of Ph+ CML and Ph+ ALL.  Another purpose is to take blood samples for laboratory studies of pharmacokinetics (the study of how the body processes a drug over time) and pharmacogenomics (the study of how genetic differences affect response to SKI-606).  Another purpose is to evaluate the quality of life of subjects receiving SKI-606.  Your participation in this study is expected to last about 52 weeks for treatment (if your leukemia has not continued to worsen and the side effects are acceptable), and two years for follow-up.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:51:03 PM